Catamaran Bio expands collaboration for CAR-NK cell engineering

By The Science Advisory Board staff writers

March 15, 2022 -- Catamaran Bio has expanded its research collaboration with the University of Minnesota to advance transposon engineering for CAR-NK cell therapies. The company also said it secured an exclusive, worldwide license to University of Minnesota's patent rights covering next-generation cell expansion technologies.

The cell expansion technologies under the patent do not require the use of feeder cells; these technologies have the potential to improve the efficiency and decrease the cost of manufacturing CAR-NK cell therapies, the company said.

The collaboration, which is with Branden Moriarity, PhD, of the University of Minnesota, will further optimize the TcBuster transposon system, a next-generation nonviral genetic modification system that has been integrated into Catamaran's TAILWIND platform.

Catamaran Bio presents preclinical data for CAR-NK cell therapy
Catamaran Bio has reported preclinical data that demonstrate the capabilities of its Tailwind platform being applied to develop CAT-248, an allogeneic...
Catamaran Bio, Bio-Techne expand CAR-NK cell collaboration
Catamaran Bio and Bio-Techne have expanded their collaboration on the development of cell engineering and cell process technologies for Catamaran's manufacturing...

Copyright © 2022

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter